ABOUT RDPAC The R&D-based Pharmaceutical Association Committee (RDPAC) is a committee of the China Association of Enterprises with Foreign Investment

Size: px

Start display at page:

Download "ABOUT RDPAC The R&D-based Pharmaceutical Association Committee (RDPAC) is a committee of the China Association of Enterprises with Foreign Investment"

诲庞
5 years ago
Views:

1 HEALTHIER CHINA THROUGH INNOVATION 创新引领健康中国

ABOUT RDPAC The R&D-based Pharmaceutical Association Committee (RDPAC) is a committee of the China Association of Enterprises with Foreign Investment (CAEFI).

2 ABOUT RDPAC The R&D-based Pharmaceutical Association Committee (RDPAC) is a committee of the China Association of Enterprises with Foreign Investment (CAEFI). It is a non-profit organization made up of 38 member companies with pharmaceutical R&D capabilities. Between them, RDPAC members have 49 plants and 30 R&D centres in China. They invest over RMB 8 billion per year in R&D in China. 关于 RDPAC RDPAC 是一个由 38 家具备研究开发能力的跨国制药企业组成的非赢利性组织, 隶属于中国外商投资企业协会目前,RDPAC 成员已在中国设立了 49 家生产工厂,30 个研发中心, 在华年研发投入约 80 亿人民币

RDPAC VISION - HEALTHIER CHINA THROUGH INNOVATION RPDAC s vision is to be a valued partner in delivering the Healthy China goal to improve the health and quality of life of the people in China.

3 RDPAC VISION - HEALTHIER CHINA THROUGH INNOVATION RPDAC s vision is to be a valued partner in delivering the Healthy China goal to improve the health and quality of life of the people in China. Provide our high-quality/innovative healthcare products and services in a socially responsible and commercially viable manner; Commit to securing patients timely access to innovative and high quality drugs; Achieve the highest standard of integrity for ethical research and business practice; Contribute to the growth of the biopharmaceutical sector in China; Support the development of a sustainable healthcare system in China. 愿景致力于成为中国实现健康中国目标以及不断提高居民和患者生活质量的重要合作伙伴 : 兼顾社会责任与行业发展, 为中国提供高质量的创新的医疗健康产品和服务 ; 为确保患者及时获得质优及创新药品而努力 ; 在研究和商业运营中保持诚信, 遵循最高标准道德规范 ; 对中国生物制药产业的发展做出积极的贡献 ; 支持中国建立可持续发展的医疗卫生体系

4 The Chinese government has boldly committed to moving the pharmaceutical industry up the value chain towards innovation and has made good progress towards this ambitious goal. 中国政府正在全力提高医药产业的创新能力, 并且已经取得一系列的卓越成绩 1

5 2RDPAC members have been long-term innovation partners with China through continuous contributions to patient safety, drug quality and treatment standards for Chinese patients. 长期以来,RDPAC 成员一直是中国医药产业的创新合作伙伴, 在提升用药安全药物质量以及治疗标准等方面作出了持续的贡献

6 Pharmaceutical R&D innovation today is conducted through global networks, and RDPAC members are integrating China into the global R&D innovation system. 在全球性合作引领医药产业研发创新的今天,RDPAC 成员有力地推动了中国融入全球医药创新体系的步伐 3

4RDPAC members have rapidly increased their investments in China R&D to 8 billion RMB per year, accounting for >50% of China s large and mid-size pharmaceutical

7 4RDPAC members have rapidly increased their investments in China R&D to 8 billion RMB per year, accounting for >50% of China s large and mid-size pharmaceutical industry R&D spending and creating ~3,000 direct high value-added R&D positions. RDPAC 成员在中国的研发创新投入正在大幅度提高, 目前总投入水平已达到每年 80 亿元, 超过中国所有大中型医药企业一年研发支出总投入的一半, 并直接创造了约 3,000 个高端研发岗位

8 These investments are primarily in disease areas identified by government and we have been ongoing partners to local research institutions in these areas with more than 210 partnerships. RDPAC 成员与中国本土研究机构结成了超过 210 对合作伙伴关系, 在中国致力于投资中国政府重点关注的疾病领域 5

9 6RDPAC members are helping to build innovative local Chinese companies by developing expertise, seeding talent and taking them global. RDPAC 成员通过提升科研技术水平培育高级管理人才以及协助拓展国际市场, 有力推进了中国创新型本土企业的发展

10 RDPAC members have helped create a distinctive RMB 6 billion local Chinese CRO industry. RDPAC 成员推动中国创建了一个总规模达 60 亿元有自主特色的研发外包产业 7

8To become a truly global innovator, in addition to making steady progress towards a thriving scientific infrastructure, China needs to provide a

11 8To become a truly global innovator, in addition to making steady progress towards a thriving scientific infrastructure, China needs to provide a supportive regulatory environment, reward innovation and continue to protect IPR. 展望将来, 中国要成为真正的全球创新者, 不仅需要提供不断完善的基础研发配套设施, 更要注重建立支持创新的监管环境制定合理的创新激励机制以及加大对知识产权的保护力度

12 The Chinese government, local companies and RDPAC members share a similar vision to see China become a leading global innovation partner. RDPAC welcomes the opportunity to continue to partner with the government to reach our joint aspiration for the benefit of Chinese patients. 中国政府本土企业以及 RDPAC 成员怀有一个共同的愿望, 即希望中国成为全球医药创新的领军者 RDPAC 期待有机会和中国政府共同努力协同发展, 实现这一愿望, 惠及更多中国患者 9

RDPAC Member List Abbott AbbVie Allergan Amgen Astellas AstraZeneca Baxter Bayer HealthCare Boehringer Ingelheim Bristol Myers Squibb Celgene Chiesi Chugai Eisai Eli Lilly Fresenius Kabi GE

13 RDPAC Member List Abbott AbbVie Allergan Amgen Astellas AstraZeneca Baxter Bayer HealthCare Boehringer Ingelheim Bristol Myers Squibb Celgene Chiesi Chugai Eisai Eli Lilly Fresenius Kabi GE Healthcare Gedeon Richter Helsinn Ipsen Kyowa Kirin LEO Pharma China Lundbeck Menarini Merck Serono MSD Mundipharma Novartis Novo Nordisk Pfizer Roche Sanofi Servier Sumitomo Takeda UCB Xian-Janssen Zambon Date Updated: March 2016

14 会员公司名录雅培艾伯维艾尔建安进安斯泰来阿斯利康百特拜耳医药保健勃林格殷格翰百时美施贵宝新基医药凯西中外制药卫材礼来费森尤斯卡比 GE 医疗匈牙利吉瑞大药厂赫尔森益普生协和发酵麒麟利奥制药灵北美纳里尼默克雪兰诺默沙东萌蒂制药诺华诺和诺德辉瑞罗氏赛诺菲施维雅住友武田优时比制药西安杨森赞邦截至 2016 年 3 月

15 China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee ADD: Room 506, Office Building 1, Landmark Tower, No.8 Dongsanhuanbei Rd. Chaoyang District, Beijing , China TEL: FAX: WEBSITE: 中国外商投资企业协会药品研制和开发行业委员会地址 : 中国北京市朝阳区东三环北路 8 号北京亮马河大厦 1 座 506 室邮编 : 电话 : 传真 : 网址 :

目录简介 1 中国慢性病与糖尿病现状 2 糖尿病的经济负担 5 在研糖尿病药物 6 全球行动与建议 7

目录简介 1 中国慢性病与糖尿病现状 2 糖尿病的经济负担 5 在研糖尿病药物 6 全球行动与建议 7 以药物创新应对糖尿病的挑战目录简介 1 中国慢性病与糖尿病现状 2 糖尿病的经济负担 5 在研糖尿病药物 6 全球行动与建议 7 以药物创新应对糖尿病的挑战简介糖尿病是一种不能治愈的病症但是确诊后该病症是可控的如能早期发现, 控制的效果会更好, 其他并发症例如心脏病肾衰以及失明亦可避免最新数据表明, 全世界的糖尿病患病率为 8.8% 1 根据国际糖尿病联盟的统计,2015 年中国的糖尿病患者达到